Motor Identity and Temporal Coherence: Parkinson's Disease as Dopaminergic Identity Drift, Essential Tremor as Cerebellar Synchrony Loss, and a Three-Level Taxonomy of Motor Identity Failure Derived from the Identity Axis Framework

This paper extends the Identity Axis Framework to the motor system, introducing the Motor Identity Class as a new table entry category with three distinct identity levels (cellular, connectivity, temporal) that are absent from all other framework entries to date. The three-level taxonomy resolves a structural puzzle: why do diseases producing the same clinical symptom family (tremor, motor instability) require categorically different treatments? The central derivation is: the level of identity failure — not the symptom — determines the drug class. The same surface phenotype (tremor) emerges from three mechanistically distinct geometry positions, each requiring a different intervention logic. Parkinson's disease is the cleanest Level 1 (cellular identity) entry in neurodegeneration. The cell of origin is the substantia nigra pars compacta (SNc) dopaminergic neuron. The Identity Anchor is NURR1 (NR4A2), the terminal selector of the dopaminergic phenotype, which directly drives TH, DAT, VMAT2, and AADC. The Convergence Hub is the HDAC4/5 axis, recruited to the nucleus by alpha-synuclein aggregates, which deacetylates histones at NURR1 target gene promoters and silences the dopaminergic identity programme. RPD = NURR1 expression / HDAC4/5 activity. The propagating alpha-synuclein aggregate is geometrically identical to the tau hub in Alzheimer's disease: a propagating protein that spreads trans-synaptically through anatomically connected networks (Braak staging I-VI), functioning as a mobile Hub that initiates identity failure at each synapse it reaches. The drug logic follows directly: HDAC4/5 selective inhibitor (Tier 2 Hub suppression) combined with NURR1 agonist (Tier 2A Identity Anchor agonism). Seven of seven literature confirmations. One novel prediction locked: RPD as a continuous predictor of phenotypic integrity outperforms TH staining alone. Essential tremor is a Level 2 (connectivity identity) entry with no propagating protein Hub. The cell of origin is the cerebellar Purkinje cell. The Identity Anchor is GRID2 (GluRdelta2), the receptor that maintains one-to-one climbing fibre to Purkinje cell specificity. The Hub is structural multi-CF innervation arising from synaptic pruning deficits. When multiple climbing fibres innervate each Purkinje cell, independent phase relationships are lost; all cells lock to the same inferior olive oscillation frequency (10-12 Hz) ; synchronised output propagates through thalamus to motor cortex; motor output collapses from smooth high-frequency averaging to a 10-12 Hz oscillation. That is the tremor. This is a Level 2 (connectivity) failure, not a Level 1 (cellular) failure: the Purkinje cell is healthy; its connectivity geometry is wrong. The drug logic follows: GRID2 restoration (gene therapy) or inferior olive de-synchronisation (harmane antagonism). The framework provides the first geometric explanation for why essential tremor improves with alcohol: ethanol suppresses inferior olive oscillation, removing the coherent synchronising input, allowing Purkinje cell independence to partially recover. Deep Brain Stimulation (DBS) is geometrically re-characterised as a Level 3 (temporal identity) hardware patch for a Level 1 software problem. 130 Hz stimulation disrupts the pathological beta-band (13-30 Hz) oscillation in the basal ganglia by driving the circuit above its coherent oscillation capacity. This explains both why DBS works (temporal identity reset) and why it has a ceiling (it does not address the underlying cellular identity failure). The framework predicts: DBS combined with HDAC4/5 inhibition and NURR1 agonism should outperform DBS alone because it adds Level 1 repair to Level 3 patch. The complete Motor Identity Class table is derived: five entries spanning PD (Level 1), Essential Tremor (Level 2), Huntington's disease (Level 1, MSN), ALS (Level 1, motor neuron), and Dystonia (Level 2-3). The anle138b cross-entry observation is noted: the same compound with confirmed activity against alpha-syn (PD), tau (AD), and PrPSc (prion) aggregation operates as a universal Tier 2 cross-entry drug for all Level 1 propagating protein Hub entries simultaneously. Four novel predictions are locked with timestamp 2026-03-09.